SI3010539T1 - Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R - Google Patents
Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4RInfo
- Publication number
- SI3010539T1 SI3010539T1 SI201431352T SI201431352T SI3010539T1 SI 3010539 T1 SI3010539 T1 SI 3010539T1 SI 201431352 T SI201431352 T SI 201431352T SI 201431352 T SI201431352 T SI 201431352T SI 3010539 T1 SI3010539 T1 SI 3010539T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antagonist
- administering
- methods
- nasal polyposis
- treating nasal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837912P | 2013-06-21 | 2013-06-21 | |
EP14305670 | 2014-05-07 | ||
EP14742021.0A EP3010539B1 (en) | 2013-06-21 | 2014-06-20 | Methods for treating nasal polyposis by administering an il-4r antagonist |
PCT/US2014/043440 WO2014205365A1 (en) | 2013-06-21 | 2014-06-20 | Methods for treating nasal polyposis by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3010539T1 true SI3010539T1 (sl) | 2019-11-29 |
Family
ID=50736018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431352T SI3010539T1 (sl) | 2013-06-21 | 2014-06-20 | Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R |
Country Status (18)
Country | Link |
---|---|
US (2) | US10059771B2 (sl) |
EP (2) | EP3010539B1 (sl) |
JP (1) | JP6463351B2 (sl) |
KR (3) | KR20160024916A (sl) |
CN (2) | CN111437387A (sl) |
AU (3) | AU2014284235B2 (sl) |
CA (1) | CA2915839A1 (sl) |
CY (1) | CY1122754T1 (sl) |
HK (1) | HK1222567A1 (sl) |
IL (1) | IL243246B (sl) |
MX (1) | MX368068B (sl) |
PL (1) | PL3010539T3 (sl) |
RS (1) | RS59354B1 (sl) |
RU (1) | RU2674680C2 (sl) |
SG (2) | SG11201509625PA (sl) |
SI (1) | SI3010539T1 (sl) |
TW (2) | TWI709411B (sl) |
WO (1) | WO2014205365A1 (sl) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
JP6463351B2 (ja) | 2013-06-21 | 2019-01-30 | サノフィ・バイオテクノロジー | Il−4rアンタゴニストの投与により鼻茸を処置する方法 |
ES2747630T3 (es) * | 2013-06-21 | 2020-03-11 | Sanofi Biotechnology | Métodos de tratamiento de poliposis nasal administrando un antagonista de IL-4R |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
KR20220029765A (ko) | 2014-02-21 | 2022-03-08 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
CN106062000B (zh) | 2014-02-28 | 2021-05-28 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗皮肤感染的方法 |
CN107206073A (zh) * | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
CA3014202A1 (en) * | 2016-02-19 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
MA46098A (fr) * | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
CN108339118A (zh) * | 2017-01-23 | 2018-07-31 | 瑞阳(苏州)生物科技有限公司 | 治疗或预防阻塞性睡眠呼吸暂停的药物组合物 |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
GB201802487D0 (en) * | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
CN108373505B (zh) * | 2018-04-20 | 2019-08-20 | 北京智仁美博生物科技有限公司 | 抗il-4r抗体及其用途 |
EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
CN113166259A (zh) * | 2018-11-09 | 2021-07-23 | 亚洲大学校产学协力团 | 对人IL-4受体α具有高亲和力的人抗体及其用途 |
CN111494625B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
AU2020231343A1 (en) * | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
CA3147068A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
AU2020349263B2 (en) | 2019-09-20 | 2023-08-17 | Maruho Co., Ltd. | Pharmaceutical composition |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
BR112022011098A2 (pt) | 2019-12-09 | 2022-09-20 | Sanofi Biotechnology | Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados |
CN117693362A (zh) * | 2021-08-02 | 2024-03-12 | 甘李药业股份有限公司 | 含有抗il-4r抗体的稳定制剂 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
DE60130466T2 (de) | 2000-07-26 | 2008-06-12 | Hououdou Co. Ltd. | Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
US7208579B2 (en) * | 2003-05-30 | 2007-04-24 | The Regents Of The University Of California | IL4 receptor antagonists for horse, dog and cat |
AU2004290017B2 (en) | 2003-11-07 | 2012-05-03 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
US7884054B2 (en) | 2003-12-22 | 2011-02-08 | Amgen Inc. | Methods for identifying functional antibodies |
EP1723173B1 (en) | 2004-02-27 | 2008-05-14 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypeptides and therapeutic uses thereof |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
RU2490278C2 (ru) * | 2007-12-21 | 2013-08-20 | Медиммун Лимитед | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
EP2271674A2 (en) * | 2008-04-02 | 2011-01-12 | Apogenix GmbH | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
EP2376656A4 (en) | 2008-12-01 | 2012-05-16 | Cincinnati Children S Hospital Medical Ct | METHODS FOR DETERMINING THE EFFECTIVENESS OF GLUCOCORTICOID TREATMENT OF SOSHOPHILIC OOPHAGITIS |
WO2010120511A2 (en) * | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Method of treating respiratory disorders |
RU2403071C1 (ru) * | 2009-09-03 | 2010-11-10 | Логина Наталия Алексеевна | Способ лечения хронических рецидивирующих воспалительных заболеваний слизистой носа и околоносовых пазух методом эндоназальной аутолимфоцитотерапии |
ES2569515T3 (es) * | 2010-03-16 | 2016-05-11 | Airsonett Ab | Tratamiento del asma, de la rinitis alérgica y mejora de la calidad del sueño mediante tratamiento con flujo aéreo laminar controlado por temperatura |
NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
UA111731C2 (uk) * | 2010-10-06 | 2016-06-10 | Рідженерон Фармасьютікалз, Інк. | Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти |
US20130052190A1 (en) * | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
RU2469737C1 (ru) * | 2011-06-28 | 2012-12-20 | Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) | Способ лечения хронического риносинусита |
BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
ES2900342T3 (es) | 2012-08-21 | 2022-03-16 | Sanofi Biotechnology | Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R |
WO2014039461A1 (en) | 2012-09-07 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
JP6463351B2 (ja) | 2013-06-21 | 2019-01-30 | サノフィ・バイオテクノロジー | Il−4rアンタゴニストの投与により鼻茸を処置する方法 |
KR20220029765A (ko) | 2014-02-21 | 2022-03-08 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
CN107206073A (zh) | 2014-11-14 | 2017-09-26 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法 |
-
2014
- 2014-06-20 JP JP2016521853A patent/JP6463351B2/ja active Active
- 2014-06-20 SG SG11201509625PA patent/SG11201509625PA/en unknown
- 2014-06-20 SI SI201431352T patent/SI3010539T1/sl unknown
- 2014-06-20 KR KR1020167000981A patent/KR20160024916A/ko active Application Filing
- 2014-06-20 EP EP14742021.0A patent/EP3010539B1/en active Active
- 2014-06-20 MX MX2015017970A patent/MX368068B/es active IP Right Grant
- 2014-06-20 TW TW103121405A patent/TWI709411B/zh active
- 2014-06-20 RS RSP20191274 patent/RS59354B1/sr unknown
- 2014-06-20 TW TW109133577A patent/TWI757893B/zh active
- 2014-06-20 US US14/310,419 patent/US10059771B2/en active Active
- 2014-06-20 WO PCT/US2014/043440 patent/WO2014205365A1/en active Application Filing
- 2014-06-20 SG SG10201710557QA patent/SG10201710557QA/en unknown
- 2014-06-20 AU AU2014284235A patent/AU2014284235B2/en active Active
- 2014-06-20 CN CN202010182762.3A patent/CN111437387A/zh active Pending
- 2014-06-20 KR KR1020217034479A patent/KR20210132232A/ko not_active IP Right Cessation
- 2014-06-20 KR KR1020237014744A patent/KR20230066127A/ko not_active Application Discontinuation
- 2014-06-20 PL PL14742021T patent/PL3010539T3/pl unknown
- 2014-06-20 RU RU2016101632A patent/RU2674680C2/ru active
- 2014-06-20 CA CA2915839A patent/CA2915839A1/en active Pending
- 2014-06-20 CN CN201480035350.XA patent/CN105517570B/zh active Active
- 2014-06-20 EP EP19187112.8A patent/EP3613432A1/en active Pending
-
2015
- 2015-12-20 IL IL243246A patent/IL243246B/en active IP Right Grant
-
2016
- 2016-09-13 HK HK16110805.6A patent/HK1222567A1/zh unknown
-
2018
- 2018-07-18 US US16/038,816 patent/US20190040146A1/en active Pending
-
2019
- 2019-10-24 CY CY20191101111T patent/CY1122754T1/el unknown
- 2019-11-07 AU AU2019261751A patent/AU2019261751B2/en active Active
-
2022
- 2022-02-25 AU AU2022201336A patent/AU2022201336A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222567A1 (zh) | 通過施用 拮抗劑治療鼻息肉症的方法 | |
HRP20181963T1 (hr) | Postupci za liječenje ili sprječavanje astme primjenom antagonista il-4r | |
IL252228A0 (en) | Methods for treating chronic sinusitis with nasal polyps by adding an il-4r antagonist | |
PL3107575T3 (pl) | Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R | |
PT3110848T (pt) | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r | |
HRP20182145T1 (hr) | Antitumorni agens koji uključuje irinotekan hidroklorid hidrat u niskoj dozi | |
EP2968458A4 (en) | DOSAGE SCHEME FOR THERAPEUTIC PROCESS | |
SG10201912898XA (en) | Methods for treating nasal polyposis by administering an il-4r antagonist | |
IL271284A (en) | Methods for treating or preventing asthma by administering an antagonist to -il-r4 | |
IL285483A (en) | Methods for the treatment of chronic sinusitis with nasal polyps by adding an il-4r antagonist | |
IL246913B (en) | Methods for treating dermatitis by administering an antagonist to -il-4r | |
IL247290A0 (en) | Methods of treating or preventing asthma by adding an il-4r antagonist |